Literature DB >> 2534733

Determination of acitretin and 13-cis-acitretin in skin.

J P Laugier1, P Berbis, C Brindley, H Bun, J M Geiger, Y Privat, A Durand.   

Abstract

The aim of the study was to investigate the concentrations of Ro 10-1670 (acitretin) and its isomeric metabolite Ro 13-7652 (cis-acitretin) after multiple oral dosing of acitretin. We used a highly sensitive HPLC method for simultaneous determination of the 2 retinoids with a quantification limit of 2 ng/ml in plasma and 10 ng/g in total skin (epidermis and dermis). In hairless rats receiving orally 8 mg/kg acitretin once daily during 8 days, blood and skin samples were taken at different time points between 5 and 96 h after the last dose. After 96 h, appreciable concentrations of Ro 10-1670, but not Ro 13-7652 could be measured in the skin, whereas both isomers were below the quantification limit in plasma. In psoriatic patients treated with a once daily dose of 30 mg acitretin, blood samples and biopsies were taken after 1 month of treatment (i.e. under steady state conditions). 24 h after the last drug intake, skin concentrations of acitretin were approximately 10 times higher than those observed in plasma. Ro 10-1670 concentrations in the skin were approximately 3-5 times higher than for Ro 13-7652 and concentrations of both isomers were higher in lesional compared to uninvolved skin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2534733

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  3 in total

Review 1.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

2.  In vivo skin penetration of acitretin in volunteers using three sampling techniques.

Authors:  C Surber; K P Wilhelm; D Bermann; H I Maibach
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

3.  The distribution of cis- and trans-acitretin in human epidermis.

Authors:  E Meyer; W Lambert; A De Leenheer; J De Bersaques; A Kint
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.